Literature DB >> 17215062

Deficits in working memory and motor performance in the APP/PS1ki mouse model for Alzheimer's disease.

Oliver Wirths1, Henning Breyhan, Stephanie Schäfer, Christian Roth, Thomas A Bayer.   

Abstract

The APP/PS1ki mouse model for Alzheimer's disease (AD) exhibits robust brain and spinal cord axonal degeneration and hippocampal CA1 neuron loss starting at 6 months of age. It expresses human mutant APP751 with the Swedish and London mutations together with two FAD-linked knocked-in mutations (PS1 M233T and PS1 L235P) in the murine PS1 gene. The present report covers a phenotypical analysis of this model using either behavioral tests for working memory and motor performance, as well as an analysis of weight development and body shape. At the age of 6 months, a dramatic, age-dependent change in all of these properties and characteristics was observed, accompanied by a significantly reduced ability to perform working memory and motor tasks. The APP/PS1ki mice were smaller and showed development of a thoracolumbar kyphosis, together with an incremental loss of body weight. While 2-month-old APP/PS1ki mice were inconspicuous in all of these tasks and properties, there is a massive age-related impairment in all tested behavioral paradigms. We have previously reported robust axonal degeneration in brain and spinal cord, as well as abundant hippocampal CA1 neuron loss starting at 6 months of age in the APP/PS1ki mouse model, which coincides with the onset of motor and memory deficits described in the present report.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17215062     DOI: 10.1016/j.neurobiolaging.2006.12.004

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  28 in total

Review 1.  APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD).

Authors:  R Lalonde; K Fukuchi; C Strazielle
Journal:  Neurosci Biobehav Rev       Date:  2012-02-21       Impact factor: 8.989

2.  Loss of tau elicits axonal degeneration in a mouse model of Alzheimer's disease.

Authors:  H N Dawson; V Cantillana; M Jansen; H Wang; M P Vitek; D M Wilcock; J R Lynch; D T Laskowitz
Journal:  Neuroscience       Date:  2010-04-29       Impact factor: 3.590

3.  Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis.

Authors:  Oliver Wirths; Christian Erck; Henrik Martens; Anja Harmeier; Constanze Geumann; Sadim Jawhar; Sathish Kumar; Gerd Multhaup; Jochen Walter; Martin Ingelsson; Malin Degerman-Gunnarsson; Hannu Kalimo; Inge Huitinga; Lars Lannfelt; Thomas A Bayer
Journal:  J Biol Chem       Date:  2010-10-22       Impact factor: 5.157

Review 4.  Weight Loss in Patients with Dementia: Considering the Potential Impact of Pharmacotherapy.

Authors:  Bart A A Franx; Ilse A C Arnoldussen; Amanda J Kiliaan; Deborah R Gustafson
Journal:  Drugs Aging       Date:  2017-06       Impact factor: 3.923

5.  Pyroglutamate amyloid β (Aβ) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease.

Authors:  Jessica L Wittnam; Erik Portelius; Henrik Zetterberg; Mikael K Gustavsson; Stephan Schilling; Birgit Koch; Hans-Ulrich Demuth; Kaj Blennow; Oliver Wirths; Thomas A Bayer
Journal:  J Biol Chem       Date:  2012-01-20       Impact factor: 5.157

Review 6.  Pyroglutamate amyloid-β (Aβ): a hatchet man in Alzheimer disease.

Authors:  Sadim Jawhar; Oliver Wirths; Thomas A Bayer
Journal:  J Biol Chem       Date:  2011-09-29       Impact factor: 5.157

7.  Intracellular accumulation of amyloid-Beta - a predictor for synaptic dysfunction and neuron loss in Alzheimer's disease.

Authors:  Thomas A Bayer; Oliver Wirths
Journal:  Front Aging Neurosci       Date:  2010-03-10       Impact factor: 5.750

8.  Amyloid plaques in PSAPP mice bind less metal than plaques in human Alzheimer's disease.

Authors:  Andreana C Leskovjan; Antonio Lanzirotti; Lisa M Miller
Journal:  Neuroimage       Date:  2009-05-28       Impact factor: 6.556

9.  Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases.

Authors:  Oliver Wirths; Tobias Bethge; Andrea Marcello; Anja Harmeier; Sadim Jawhar; Paul J Lucassen; Gerd Multhaup; David L Brody; Thomas Esparza; Martin Ingelsson; Hannu Kalimo; Lars Lannfelt; Thomas A Bayer
Journal:  J Neural Transm (Vienna)       Date:  2009-10-13       Impact factor: 3.575

10.  Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model.

Authors:  Oliver Wirths; Henning Breyhan; Holger Cynis; Stephan Schilling; Hans-Ulrich Demuth; Thomas A Bayer
Journal:  Acta Neuropathol       Date:  2009-06-23       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.